ARRAY BIOPHARMA ($ARRY) posted quarterly earnings results on Tuesday, May 6th. The company reported earnings of $0.13 per share, beating estimates of $0.09 by $0.04 ...

BOULDER, Colo., June 27, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI™ capsules in combination with ...

Clinical trial results from Array BioPharma's (Nasdaq: ARRY) wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, were presented this weekend at the European Society of Medical ...

After Array BioPharma (NASDAQ: ARRY) announced quarterly results and shared some clinical news with investors on Tuesday, shares of the cancer-focused clinical-stage biotech jumped and were up 18% as ...

Following Array Biopharma Inc (NASDAQ:ARRY) reporting positive top line results from part 2 of a late-stage study of its combo treatment candidate for metastatic and BRAF-mutant melanoma, Leerink ...

Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis. Array BioPharma ...

Clovis Oncology, Inc. and Array BioPharma have announced an agreement for the discovery of a novel KIT inhibitor targeting resistance mutations for the treatment of GIST. GIST is a gastrointestinal ...

Success in trials of new drugs for metastatic melanoma propelled the stock of Array Biopharma (NASDAQ: ARRY) 115% in 2016. However, after a string of successes, Array hit a setback earlier this week: ...

* Point72 Asset Management L.P reports 5.4 percent passive stake in Array Biopharma Inc as of September 11, 2017 - SEC filing‍ Source text: Further company coverage: ...